Azacitidine - PDFSEARCH.IO - Document Search Engine

Azacitidine
Results: 65

#	Item
1	Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma Add to Reading List Source URL: www.ehoonline.org Language: English Triazines Orphan drugs Acute leukemia Myeloid leukemia Azacitidine Acute myeloid leukemia Myelodysplastic syndrome Decitabine Leukemia Medicine Oncology Nucleosides
2	HIGHLIGHTS OF PRESCRIBING INFORMATION Add to Reading List Source URL: assets1.celgene.com Language: English - Date: 2014-02-13 13:42:04 Azacitidine Nucleosides Triazines lactams Myelodysplastic syndrome Celgene Adverse effect Medicine Health Orphan drugs
3 $June 14, 2013 Astex Pharmaceuticals Announces Presentation of Updated Results of SGI[removed]Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology As$	June 14, 2013 Astex Pharmaceuticals Announces Presentation of Updated Results of SGI[removed]Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology As Add to Reading List Source URL: astx.com Language: English Oncology Orphan drugs Myelodysplastic syndrome Syndromes Azacitidine Decitabine Cyclacel Medicine Nucleosides Triazines
4	Abst. No. Outcomes of Intermediate or High Risk Myelodysplastic Syndromes (MDS) Patients Post Azacitidine and/or Decitabine Treatment Failures with SGI-110, a Novel Second Generation Hypomethylating Agent (HMA) Add to Reading List Source URL: astx.com Language: English Triazines Orphan drugs Azacitidine lactams Myelodysplastic syndrome Decitabine Hypomethylating agent Lenalidomide Acute myeloid leukemia Medicine Oncology Nucleosides
5 $DNA demethylation activity over time and safety of 3 different dose-escalation regimens of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in the treatment of relapsed/refractory patients with MDS and AML$	DNA demethylation activity over time and safety of 3 different dose-escalation regimens of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in the treatment of relapsed/refractory patients with MDS and AML Add to Reading List Source URL: astx.com Language: English Pharmacology Azacitidine lactams Chemistry Decitabine Hypomethylating agent Nucleosides Triazines Medicine
6	Results From the Dose Escalation Phase of a Randomized Phase 1–2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapse Add to Reading List Source URL: astx.com Language: English - Date: 2013-05-20 15:28:50 Triazines Epigenetics Biology Acute leukemia Myeloid leukemia Acute myeloid leukemia DNA methyltransferase Azacitidine Decitabine Oncology Medicine Nucleosides
7 $Study of the correlation of baseline biomarkers and DNA demethylation to clinical responses in a phase 1/2, randomized study of SGI-110, a novel subcutaneous hypomethylating agent in the treatment of relapsed/refractory$	Study of the correlation of baseline biomarkers and DNA demethylation to clinical responses in a phase 1/2, randomized study of SGI-110, a novel subcutaneous hypomethylating agent in the treatment of relapsed/refractory Add to Reading List Source URL: astx.com Language: English Medicine Epigenetics Biology Acute leukemia Myeloid leukemia Azacitidine Acute myeloid leukemia Hypomethylating agent Decitabine Oncology Nucleosides Triazines
8	First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML) Jean Pierre Issa, MD Fels Institute, Temple Univ Add to Reading List Source URL: astx.com Language: English Triazines Acute leukemia Myeloid leukemia Acute myeloid leukemia Orphan drugs Azacitidine DNA methyltransferase Leukemia Epigenetics Oncology Medicine Nucleosides
9	First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous hypomethylating agent, in 102 patients with Intermediate or High Risk MDS or CMML On Behalf of the SGI-110 Investigative Team Guillerm Add to Reading List Source URL: astx.com Language: English Pharmacology Azacitidine lactams Chemistry Decitabine Hypomethylating agent DNA methyltransferase Nucleosides Triazines Medicine
10	Microsoft PowerPoint - LLS1104 - MDS slides - on background v14 (for pdf) [Compatibility Mode] Add to Reading List Source URL: www.cancereducation.com Language: English - Date: 2015-04-02 11:28:05 Nucleosides Triazines Immunosuppressants Lenalidomide Azacitidine Decitabine Erythropoietin International Prognostic Scoring System Hypomethylating agent Medicine Oncology Pharmacology